Under the agreement between the companies, Natco will be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the US and Canada.
According to Akorn, the two ANDA drug products will have a combined current market size of approximately $875 million.
“This arrangement helps in bringing down development expense and compete with vertically integrated firms in a competitive generic business,” said Chowdary Nannapaneni, Natco Pharma’s chairman and managing director.